IXHL.US Incannex Healthcare Inc.

Healthcare Biotechnology USA Stocks
1.97 USD
Close of Nov 15, 2026
1.91 14.91
Market cap
USD 24.7M
P/E
-
P/B
0.37x
ROE
-11.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.

Is IXHL.US undervalued?

Graham number

The Graham number of Incannex Healthcare Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Incannex Healthcare Inc. fundamental analysis

No fundamental analysis for Incannex Healthcare Inc. yet.

Incannex Healthcare Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with gen…

Full company profile